Results 211 to 220 of about 36,256 (261)

Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle [PDF]

core   +1 more source

Agnostic phase II, multicenter, single-arm study with DURVAlumab plus carboplatin or cisplatin and etoposide as first-line treatment in extensive stage - Extrapulmonary Small Cell Carcinoma (EPSCC) patients - DURVASCC trial (GOIRC-01-2021). [PDF]

BMC Cancer
Damato A, Maglietta G, Antonuzzo L, Berardi R, Buonadonna A, Brighi N, Cinieri S, Di Micco C, Gelsomino F, Grossi F, Martinelli E, Cesario S, Pusceddu S, Spada F, Iachetta F, Gervasi E, Ciardiello G, Normanno N, Pinto C.   +18 more
europepmc   +1 more source

Emerging Therapeutic Synergies: Combining PD-1 Inhibitors With Poly-ADP-Ribose Polymerase (PARP) Inhibitors in the Treatment of Gynecologic Cancers. [PDF]

Cureus
Mohamed Azhar MS, Loh Z, Mutamba FT, Algahiny A, Yunusa NM, Paramasevon S, Almusarhed M.   +6 more
europepmc   +1 more source

Comparative efficacy and safety of targeted therapeutics or immunotherapy agents combined with chemotherapy as first-line treatment for advanced biliary tract cancer: a systematic review and network meta-analysis. [PDF]

BMC Cancer
Ma H, Wang Z, Tong Y, Li H, Han Y, He D.
europepmc   +1 more source

Expression of carcinoma ecotypes in the tumor microenvironment predicts response to neoadjuvant therapy in early-stage breast cancer. [PDF]

Sci Rep
Asleh K, Bethune G, Marcato P.
europepmc   +1 more source

Precision targeted-immunotherapy for BRAF V600E and MET-amplified biliary tract cancer: two case reports. [PDF]

Oncologist
He X, Xie S, Jia C, Wu X, Chen Z, Wang T.   +5 more
europepmc   +1 more source

Impact of LEAP-012 and EMERALD-1 in the management of HCC. [PDF]

JHEP Rep
Singal AG, Garcia-Reyes K, Kelley RK, Kim E.   +3 more
europepmc   +1 more source

Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in <i>STK11, KEAP1</i>, or <i>KRAS</i>: the TRITON study. [PDF]

Ther Adv Med Oncol
Skoulidis F, Borghaei H, Garon EB, Leal TA, Kaufman J, Liu SV, Nadler E, Patel SP, Peters S, Ricciuti B, Gautam A, Emeribe U, Luciani-Silverman L, Heymach JV.   +13 more
europepmc   +1 more source

Durvalumab in Advanced Biliary Tract Cancer: Real-World Data From a Large Cohort of Patients Across Multiple International Centers. [PDF]

Liver Int
Rimini M, Fornaro L, Ikeda M, Abidoye O, Lucchetti J, Antonuzzo L, Kim JW, Nichetti F, Saborowski A, Pressiani T, Vivaldi C, Rapposelli IG, Peeters F, Braconi C, Pinato DJ, Tamburini E, Pircher C, Tamberi S, Castet F, Verrico M, Parisi A, Couto N, Chon HJ, Martirena A, Lamarca A, Landriscina M, Fimkelmeier F, Oneda E, Avallone A, Dell'Aquila E, Perkhofer L, Kim IH, Pinto CMS, Garajova I, Kang B, Corallo S, Fenocchio E, Farinea G, Pastorino A, Diana A, Changhoon Y, Schirripa M, Rodriquenz MG, Scartozzi M, Zumstein L, Ghidini M, Prager GW, Aprile G, Spinelli GP, Yung-Yeh S, Chan S, Warmington E, Lancianese A, Bekaii-Saab T, Lavacchi D, Kang M, Lonardi S, Vogel A, Prete AA, Bozzarelli S, Salani F, Persano M, Masi G, Balsano R, Niger M, Camera S, Passeri L, Ferrara M, Satake T, Rimassa L, Casadei-Gardini A.   +70 more
europepmc   +1 more source

Acute Cerebellitis Due to Administration of Durvalumab for Recurrent Endometrial Cancer: A Case Report. [PDF]

Cureus
Kawahara H, Taketoshi K, Nagano T, Matsuo T, Kobayashi H.   +4 more
europepmc   +1 more source